

comments to Dr. Armitage by mail or courier. Commenters planning to attend the meeting in person are asked to bring 35 copies of their comments for public distribution. *Oral Comments:* Requests to provide oral comments must be in writing (e-mail or fax) and received by Dr. Armitage no later than September 14, 2005 to reserve time on the meeting agenda. Presentation time for oral comment will typically be about five minutes per speaker, but may be reduced depending on time availability and the number of requests.

*Meeting Accommodations:* Individuals requiring special accommodation to access the public meeting listed above should contact the DFO at least five business days prior to the meeting so that appropriate arrangements can be made.

Dated: August 23, 2005.

**Anthony Maciorowski,**

*Acting Director, EPA Science Advisory Board Staff Office.*

[FR Doc. 05-17198 Filed 8-29-05; 8:45 am]

**BILLING CODE 6560-50-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[RFA AA169]

#### Building for Local Organizations in the Republic of South Africa and the Kingdoms of Lesotho and Swaziland; Notice of Availability of Funds—Amendment

A notice announcing the availability of Fiscal Year (FY) 2005 funds for a cooperative agreement for Building for Local Organizations in the Republic of South Africa and the Kingdoms of Lesotho and Swaziland, was published in the **Federal Register**, August 12, 2005, Volume 70, Number 155, pages 47209-47214.

This notice is amended as follows:

Page 47210, Approximate Total Funding: delete \$500,000, and replace with \$5,000,000. Page 47210, Approximate Average Award, delete \$100,000, and replace with \$500,000-\$1,000,000. Page 47210, Ceiling of Award Range, delete \$100,000, and replace with \$1,000,000.

Dated: August 23, 2005.

**William P. Nichols,**

*Director, Procurement and Grants Office, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services.*

[FR Doc. 05-17177 Filed 8-29-05; 8:45 am]

**BILLING CODE 4163-18-U**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

*Name of Committee:* Vaccines and Related Biological Products Advisory Committee.

*General Function of the Committee:*

To provide advice and recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held via teleconference on September 22, 2005 from 1:30 p.m. to 5 p.m.

*Location:* NIH campus, Food and Drug Administration Bldg. 29B, Conference Room C, 8800 Rockville Pike, Bethesda, MD. This meeting will be held by teleconference. The public is welcome to attend the meeting at the above location. A speaker phone will be provided at the specified location for public participation in this meeting. Important information about transportation and directions to the NIH campus, parking, and security procedures is available on the internet at <http://www.nih.gov/about/visitor/index.htm>. Visitors must show two forms of identification such as a Federal employee badge, driver's license, passport, green card, etc. If you are planning to drive to and park on the NIH campus, you must enter at the South Drive entrance of the campus, which is located on Wisconsin Ave. (the medical center metro entrance), and allow extra time for vehicle inspection. Detailed information about security procedures is located at <http://www.nih.gov/about/visitorsecurity.htm>. Due to the limited available parking, visitors are encouraged to use public transportation.

*Contact Person:* Christine Walsh or Denise Royster, Center for Biologics Evaluation and Research (HFM-71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314 or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code

3014512391. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* The committee will hear an overview of the research of the Laboratory of Retroviruses and the Laboratory of Immunoregulation, Division of Viral Products, and the Laboratory of Respiratory and Special Pathogens and the Laboratory of Methods Development and Quality Control, Division of Bacterial Parasitic and Allergenic Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research (CBER), and in closed session will discuss the reports from the Laboratory Site Visits of April 18 and 19, 2005, and June 16, 2005.

*Procedure:* On September 22, 2005, from 1:30 p.m. to 4 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by September 15, 2005. Oral presentations from the public will be scheduled between approximately 3 p.m. to 4 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before September 15, 2005, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

*Closed Committee Deliberations:* On September 22, 2005, from 4 p.m. to 5 p.m. the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). The committee will discuss a review of internal research programs in the Office of Vaccines Research and Review, Division of Viral Products and Division of Bacterial Parasitic and Allergenic Products, CBER.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Christine Walsh or Denise Royster (see **CONTACT PERSON**) at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).